These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

122 related items for PubMed ID: 16159570

  • 21. Prevention and treatment of diabetic nephropathy: the program for irbesartan mortality and morbidity evaluation.
    Ravera M, Ratto E, Vettoretti S, Parodi D, Deferrari G.
    J Am Soc Nephrol; 2005 Mar; 16 Suppl 1():S48-52. PubMed ID: 15938034
    [Abstract] [Full Text] [Related]

  • 22. A multicenter, randomized, double-blind comparison of the efficacy and safety of irbesartan and enalapril in adults with mild to moderate essential hypertension, as assessed by ambulatory blood pressure monitoring: the MAPAVEL Study (Monitorización Ambulatoria Presión Arterial APROVEL).
    Coca A, Calvo C, García-Puig J, Gil-Extremera B, Aguilera MT, de la Sierra A, Martín-Hidalgo A, Marín R, MAPAVEL Investigators (Monitorizacíon Ambulatoria Presión Arterial APROVEL).
    Clin Ther; 2002 Jan; 24(1):126-38. PubMed ID: 11833827
    [Abstract] [Full Text] [Related]

  • 23. The effects of dual blockade of the renin-angiotensin system on urinary protein and transforming growth factor-beta excretion in 2 groups of patients with IgA and diabetic nephropathy.
    Song JH, Lee SW, Suh JH, Kim ES, Hong SB, Kim KA, Kim MJ.
    Clin Nephrol; 2003 Nov; 60(5):318-26. PubMed ID: 14640237
    [Abstract] [Full Text] [Related]

  • 24. Valsartan combined with clopidogrel and/or leflunomide for the treatment of progressive immunoglobulin A nephropathy.
    Cheng G, Liu D, Margetts P, Liu L, Zhao Z, Liu Z, Tang L, Fang Y, Li H, Guo Y, Chen F, Liu F.
    Nephrology (Carlton); 2015 Feb; 20(2):77-84. PubMed ID: 25358874
    [Abstract] [Full Text] [Related]

  • 25. Effect of amlodipine, efonidipine, and trichlormethiazide on home blood pressure and upper-normal microalbuminuria assessed by casual spot urine test in essential hypertensive patients.
    Hosaka M, Inoue R, Satoh M, Watabe D, Hanazawa T, Ohkubo T, Asayama K, Obara T, Imai Y, J-HOME-ALB Study group..
    Clin Exp Hypertens; 2018 Feb; 40(5):468-475. PubMed ID: 29172732
    [Abstract] [Full Text] [Related]

  • 26. [Efficacy observation of treating diabetic nephropathy by shenshuaining granule combined telmisartan tablet].
    Li BY, Peng H, Xiong DL, Yi J, Chen H.
    Zhongguo Zhong Xi Yi Jie He Za Zhi; 2015 Feb; 35(2):142-6. PubMed ID: 25881456
    [Abstract] [Full Text] [Related]

  • 27. Treatment with irbesatan may improve slit diaphragm alterations in rats with adriamycin-induced nephropathy.
    Wang N, Wei RB, Li P, Li QP, Yang X, Yang Y, Huang MJ, Wang R, Yin Z, Lv Y, Chen XM.
    J Renin Angiotensin Aldosterone Syst; 2016 Feb; 17(2):1470320316646884. PubMed ID: 27169889
    [Abstract] [Full Text] [Related]

  • 28. [Comparison of the antihypertensive activity of fosinopril and irbesartan].
    Angulo E, Robles NR, Grois J, Barquero A, Pérez Miranda M.
    An Med Interna; 2002 Nov; 19(11):571-5. PubMed ID: 12522893
    [Abstract] [Full Text] [Related]

  • 29. Irbesartan delays progression of nephropathy as measured by estimated glomerular filtration rate: post hoc analysis of the Irbesartan Diabetic Nephropathy Trial.
    Evans M, Bain SC, Hogan S, Bilous RW, Collaborative Study Group participants.
    Nephrol Dial Transplant; 2012 Jun; 27(6):2255-63. PubMed ID: 22172728
    [Abstract] [Full Text] [Related]

  • 30. [The effects and mechanism of Tripterygium wilfordii Hook F combination with irbesartan on urinary podocyte excretion in diabetic nephropathy patients].
    Ma RX, Zhao N, Zhang W.
    Zhonghua Nei Ke Za Zhi; 2013 Jun; 52(6):469-73. PubMed ID: 24059992
    [Abstract] [Full Text] [Related]

  • 31. Telmisartan and irbesartan therapy in type 2 diabetic patients treated with rosiglitazone: effects on insulin-resistance, leptin and tumor necrosis factor-alpha.
    Derosa G, Cicero AF, D'Angelo A, Ragonesi PD, Ciccarelli L, Piccinni MN, Pricolo F, Salvadeo SA, Ferrari I, Gravina A, Fogari R.
    Hypertens Res; 2006 Nov; 29(11):849-56. PubMed ID: 17345784
    [Abstract] [Full Text] [Related]

  • 32. [Effect of Chinese herbal therapy on T-lymphocytes of IgA nephropathy patients: a clinical observation].
    Chen XJ, Yu DJ, Yu RH, Su QM, Xu YG, He Y, Liu QQ.
    Zhongguo Zhong Xi Yi Jie He Za Zhi; 2014 Jul; 34(7):786-9. PubMed ID: 25137840
    [Abstract] [Full Text] [Related]

  • 33. An economic evaluation of irbesartan in the treatment of patients with type 2 diabetes, hypertension and nephropathy: cost-effectiveness of Irbesartan in Diabetic Nephropathy Trial (IDNT) in the Belgian and French settings.
    Palmer AJ, Annemans L, Roze S, Lamotte M, Rodby RA, Cordonnier DJ.
    Nephrol Dial Transplant; 2003 Oct; 18(10):2059-66. PubMed ID: 13679481
    [Abstract] [Full Text] [Related]

  • 34. [Multicentered, randomized, controlled clinical trial on patients with IgA nephropathy of Qi-yin deficiency syndrome type].
    Chen XM, Chen YP, Chen J.
    Zhongguo Zhong Xi Yi Jie He Za Zhi; 2007 Feb; 27(2):101-5. PubMed ID: 17342992
    [Abstract] [Full Text] [Related]

  • 35. A clinical trial in type 2 diabetic nephropathy.
    Lewis EJ, Hunsicker LG, Rodby RA, Collaborative Study Group.
    Am J Kidney Dis; 2001 Oct; 38(4 Suppl 1):S191-4. PubMed ID: 11576953
    [Abstract] [Full Text] [Related]

  • 36. Effect of dual blockade of the renin-angiotensin system on the progression of type 2 diabetic nephropathy: a randomized trial.
    Fernandez Juarez G, Luño J, Barrio V, de Vinuesa SG, Praga M, Goicoechea M, Cachofeiro V, Nieto J, Fernández Vega F, Tato A, Gutierrez E, PRONEDI Study Group.
    Am J Kidney Dis; 2013 Feb; 61(2):211-8. PubMed ID: 22939518
    [Abstract] [Full Text] [Related]

  • 37. Angiotensin blockade and progressive loss of kidney function in hemodialysis patients: a randomized controlled trial.
    Kjaergaard KD, Peters CD, Jespersen B, Tietze IN, Madsen JK, Pedersen BB, Novosel MK, Laursen KS, Bibby BM, Strandhave C, Jensen JD.
    Am J Kidney Dis; 2014 Dec; 64(6):892-901. PubMed ID: 25011693
    [Abstract] [Full Text] [Related]

  • 38. Serum levels of the advanced glycation end products Nepsilon-carboxymethyllysine and pentosidine are not influenced by treatment with the angiotensin receptor II type 1 blocker irbesartan in patients with type 2 diabetic nephropathy and hypertension.
    Busch M, Franke S, Wolf G, Rohde RD, Stein G, Collaborative Study Group.
    Nephron Clin Pract; 2008 Dec; 108(4):c291-7. PubMed ID: 18434751
    [Abstract] [Full Text] [Related]

  • 39. Irbesartan for the treatment of hypertension in patients with the metabolic syndrome: a sub analysis of the Treat to Target post authorization survey. Prospective observational, two armed study in 14,200 patients.
    Kintscher U, Bramlage P, Paar WD, Thoenes M, Unger T.
    Cardiovasc Diabetol; 2007 Apr 03; 6():12. PubMed ID: 17407587
    [Abstract] [Full Text] [Related]

  • 40. Independent and additive impact of blood pressure control and angiotensin II receptor blockade on renal outcomes in the irbesartan diabetic nephropathy trial: clinical implications and limitations.
    Pohl MA, Blumenthal S, Cordonnier DJ, De Alvaro F, Deferrari G, Eisner G, Esmatjes E, Gilbert RE, Hunsicker LG, de Faria JB, Mangili R, Moore J, Reisin E, Ritz E, Schernthaner G, Spitalewitz S, Tindall H, Rodby RA, Lewis EJ.
    J Am Soc Nephrol; 2005 Oct 03; 16(10):3027-37. PubMed ID: 16120823
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.